Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 12, Issue 9, Pages 2532-2537Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1600-6143.2012.04133.x
Keywords
Immunotherapy; interleukin-2; nonhuman primates; T-regulatory cells
Categories
Funding
- NIH-NIAID [ROIA137692]
- NIH/NIAID [5R01 AI50987-03]
- NIH [R00000000008108]
- [5U19DK080652-02 NHL-BI]
- [POI-HL18646]
Ask authors/readers for more resources
IL-2 is a known potent T cell growth factor that amplifies lymphocyte responses in vivo. This capacity has led to the use of high-dose IL-2 to enhance T cell immunity in patients with AIDS or cancer. However, more recent studies have indicated that IL-2 is also critical for the development and peripheral expansion of regulatory T cells (Tregs). In the current study, low-dose IL-2 (1 million IU/m2 BSA/day) was administered to expand Tregs in vivo in naive nonhuman primates. Our study demonstrated that low-dose IL-2 therapy significantly expanded peripheral blood CD4+ and CD8+ Tregs in vivo with limited expansion of non-Treg cells. These expanded Tregs are mainly CD45RA- Foxp3 high activated Tregs and demonstrated potent immunosuppressive function in vitro. The results of this preclinical study can serve as a basis to develop Treg immunotherapy, which has significant therapeutic potential in organ/cellular transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available